VALN - Pfizer and Valneva to test a three-dose schedule for Lyme disease vaccine candidate

Reporting new Phase 2 data for their Lyme disease vaccine candidate, VLA15, Pfizer (NYSE:PFE) and Valneva (NASDAQ:VALN) said on Friday that the companies have decided to move forward a three-dose series vaccination schedule in a future Phase 3 trial. Pfizer (PFE) and Valneva (VALN) have tested a two-dose schedule and a three-dose schedule in the mid-stage trial, which involved groups aged 5-11, 12-17, and 18-65 years. While both schedules were found to be immunogenic against the disease, the antibody levels were higher in those who received the three-dose primary series. The findings have led to the selection of a three-dose regimen for the Phase 3 trial, which is set to start in 2022, subject to regulatory clearance. Meanwhile, the Phase 2 VLA15-221 trial is currently ongoing, and its initial pediatric data are expected in H1 2022. Read: Valneva (VALN) ADRs soared in January after the company reported the potential of its investigational

For further details see:

Pfizer and Valneva to test a three-dose schedule for Lyme disease vaccine candidate